Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 50090-7365
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 50090-7365). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
This text shows a graph representing the cumulative percentage of patients taking Donepezil Hydrochloride 10 mg/day and placebo, in relation to ADCS-ADL change from baseline. The graph displays the percentages of patients at different levels of change.*
Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
This text provides information on the change from baseline in clinical improvement and decline observed with two different doses of Donepezil Hydrochloride (23 mg/day and 10 mg/day) over a span of 12 to 18 weeks of drug treatment. The data is presented as LS mean with standard error.*
Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
This text appears to be a medication dosage chart for Donepezil Hydrochloride. It indicates different dosage levels of 23 mg/day and 10 mg/day. It also includes a rating scale for assessing the level of improvement or change in the patient's condition based on the CIBIC-plus Rating scale.*
Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
The text seems to list different categories related to the percentage of patient improvement in a particular condition. It includes mentions of improvements, placebo effects, and changes in conditions. Additionally, it references a CIBIC-plus Rating, which may be used to evaluate overall clinical status in specific healthcare settings.*
Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
This text appears to be describing a comparison of treatments for ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) Change from Baseline. The treatments being compared are Donepezil Hydrochloride at 10mg/day, Donepezil Hydrochloride at 5mg/day, and a placebo. The results seem to show clinical improvement with Donepezil Hydrochloride at 10mg/day and clinical decline with the placebo. The text also mentions "Weeks of Drug Treatment" as a factor in the comparison.*
Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
This description provides information about a study involving different treatment groups receiving Donepezil Hydrochloride, along with a placebo group, and their respective changes in ADAS-cog scores. The graph displays the change from baseline for each treatment group, showing the effectiveness of the different dosages of Donepezil Hydrochloride compared to placebo.*
Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
This is not-available.*
Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
This is a comparison of the change from baseline in patients undergoing drug treatment with Donepezil Hydrochloride 10 mg/day versus placebo over 3 months. The text mentions assessing clinical improvement based on the mean values.*
Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
This text provides a graph showing the cumulative percentage of patients who experienced a change in SIB (Severe Impairment Battery) score from baseline while taking Donepazil Hydrochloride 10 mg/day compared to a placebo. The graph shows the distribution of SIB change for both treatment groups.*
Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
This text describes the change from baseline in activities of daily living (ADL) as measured by the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADCS-ADL) after 3 months of drug treatment with Donepezil Hydrochloride 10 mg/day compared to a placebo. The text suggests that there may be clinical improvement in ADL when treated with Donepezil Hydrochloride based on mean values.*
Chemical Structure (Donepezil Str)
Label Image (Lbl500907365)
This is a product label for Donepezil Hydrochloride tablets, containing 5mg per tablet. The product number is 6310-0 with a shelf life of 90 tablets. It is recommended to store this medication at 68-77 degrees Fahrenheit.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
